Autor: "Prado-Vázquez, Guillermo" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Multi-omics Characterization of Response to PD-1 Inhibitors in Advanced Melanoma.
Autorzy:: Trilla-Fuertes L; Molecular Oncology Laboratory, Hospital Universitario La Paz-IdiPAZ, 28046 Madrid, Spain.
Gámez-Pozo A; Molecular Oncology Laboratory, Hospital Universitario La Paz-IdiPAZ, 28046 Madrid, Spain.; Biomedica Molecular Medicine SL, 28049 Madrid, Spain.
Prado-Vázquez G; Molecular Oncology Laboratory, Hospital Universitario La Paz-IdiPAZ, 28046 Madrid, Spain.; Biomedica Molecular Medicine SL, 28049 Madrid, Spain.
López-Vacas R; Molecular Oncology Laboratory, Hospital Universitario La Paz-IdiPAZ, 28046 Madrid, Spain.
Soriano V; Instituto Valenciano de Oncología, 46009 Valencia, Spain.; Spanish Melanoma Group (GEM), 08024 Barcelona, Spain.
Garicano F; Spanish Melanoma Group (GEM), 08024 Barcelona, Spain.; Hospital de Galdakao, 48960 Galdakao, Spain.
Lecumberri MJ; Spanish Melanoma Group (GEM), 08024 Barcelona, Spain.; Complejo Hospitalario de Navarra, 31008 Pamplona, Spain.
Rodríguez de la Borbolla M; Spanish Melanoma Group (GEM), 08024 Barcelona, Spain.; Hospital de Valme, 41014 Sevilla, Spain.
Majem M; Spanish Melanoma Group (GEM), 08024 Barcelona, Spain.; Hospital de la Santa Creu i Sant Pau, 08001 Barcelona, Spain.
Pérez-Ruiz E; Spanish Melanoma Group (GEM), 08024 Barcelona, Spain.; Unidad de Gestión Clínica Intercentros (UGCI) de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospitales Universitarios Regional y Virgen de la Victoria, 29010 Málaga, Spain.
González-Cao M; Spanish Melanoma Group (GEM), 08024 Barcelona, Spain.; Hospital Quirón Dexeus, 08028 Barcelona, Spain.
Oramas J; Spanish Melanoma Group (GEM), 08024 Barcelona, Spain.; Hospital Universitario de Canarias-San Cristóbal de la Laguna, 38320 Tenerife, Spain.
Magdaleno A; Spanish Melanoma Group (GEM), 08024 Barcelona, Spain.; Hospital Universitario de Elche y Vega Baja, 03203 Alicante, Spain.
Fra J; Spanish Melanoma Group (GEM), 08024 Barcelona, Spain.; Hospital Universitario Río Hortega, 47012 Valladolid, Spain.
Martín-Carnicero A; Spanish Melanoma Group (GEM), 08024 Barcelona, Spain.; Hospital San Pedro, 27347 Logroño, Spain.
Corral M; Spanish Melanoma Group (GEM), 08024 Barcelona, Spain.; Hospital Clínico Lozano Blesa, 50009 Zaragoza, Spain.
Puértolas T; Spanish Melanoma Group (GEM), 08024 Barcelona, Spain.; Hospital Universitario Miguel Servet, 50009 Zaragoza, Spain.
Ramos-Ruiz R; Genomics Unit, Parque Científico de Madrid, 28049 Madrid, Spain.
Dittmann A; Functional Genomics Center Zurich, University/ETH Zurich, 8092 Zurich, Switzerland.
Nanni P; Functional Genomics Center Zurich, University/ETH Zurich, 8092 Zurich, Switzerland.
Fresno Vara JÁ; Molecular Oncology Laboratory, Hospital Universitario La Paz-IdiPAZ, 28046 Madrid, Spain.; Biomedica Molecular Medicine SL, 28049 Madrid, Spain.; CIBERONC, ISCIII, 28222 Madrid, Spain.
Espinosa E; Spanish Melanoma Group (GEM), 08024 Barcelona, Spain.; CIBERONC, ISCIII, 28222 Madrid, Spain.; Medical Oncology Service, Hospital Universitario La Paz, 28046 Madrid, Spain.; Pokaż więcej
Źródło:: Cancers [Cancers (Basel)] 2023 Sep 03; Vol. 15 (17). Date of Electronic Publication: 2023 Sep 03.
Typ publikacji:: Journal Article

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: A Novel Molecular Analysis Approach in Colorectal Cancer Suggests New Treatment Opportunities.
Autorzy:: López-Camacho E; Molecular Oncology Lab, La Paz University Hospital-IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain.; Biomedica Molecular Medicine SL, C/Faraday 7, 28049 Madrid, Spain.
Prado-Vázquez G; Molecular Oncology Lab, La Paz University Hospital-IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain.; Biomedica Molecular Medicine SL, C/Faraday 7, 28049 Madrid, Spain.
Martínez-Pérez D; Medical Oncology Service, La Paz University Hospital, Paseo de la Castellana 261, 28046 Madrid, Spain.
Ferrer-Gómez M; Molecular Oncology Lab, La Paz University Hospital-IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain.
Llorente-Armijo S; Molecular Oncology Lab, La Paz University Hospital-IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain.
López-Vacas R; Molecular Oncology Lab, La Paz University Hospital-IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain.
Díaz-Almirón M; Biostatistics Unit, La Paz University Hospital-IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain.
Gámez-Pozo A; Molecular Oncology Lab, La Paz University Hospital-IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain.; Biomedica Molecular Medicine SL, C/Faraday 7, 28049 Madrid, Spain.
Vara JÁF; Molecular Oncology Lab, La Paz University Hospital-IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain.; Biomedical Research Networking Center on Oncology-CIBERONC, Carlos III Healthy Institute ISCIII, 28029 Madrid, Spain.
Feliu J; Medical Oncology Service, La Paz University Hospital, Paseo de la Castellana 261, 28046 Madrid, Spain.; Biomedical Research Networking Center on Oncology-CIBERONC, Carlos III Healthy Institute ISCIII, 28029 Madrid, Spain.; Translational Oncology Group, La Paz University Hospital-IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain.; Cátedra UAM-Amgen, Universidad Autónoma de Madrid, Ciudad Universitaria de Cantoblanco, 28049 Madrid, Spain.
Trilla-Fuertes L; Molecular Oncology Lab, La Paz University Hospital-IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain.; Translational Oncology Group, La Paz University Hospital-IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain.; Pokaż więcej
Źródło:: Cancers [Cancers (Basel)] 2023 Feb 09; Vol. 15 (4). Date of Electronic Publication: 2023 Feb 09.
Typ publikacji:: Journal Article

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Sorting Transcriptomics Immune Information from Tumor Molecular Features Allows Prediction of Response to Anti-PD1 Therapy in Patients with Advanced Melanoma.
Autorzy:: Trilla-Fuertes L; Molecular Oncology Lab, Hospital Universitario La Paz-IdiPAZ, 28046 Madrid, Spain.
Gámez-Pozo A; Molecular Oncology Lab, Hospital Universitario La Paz-IdiPAZ, 28046 Madrid, Spain.; Biomedica Molecular Medicine SL, 28049 Madrid, Spain.
Prado-Vázquez G; Molecular Oncology Lab, Hospital Universitario La Paz-IdiPAZ, 28046 Madrid, Spain.; Biomedica Molecular Medicine SL, 28049 Madrid, Spain.
López-Vacas R; Molecular Oncology Lab, Hospital Universitario La Paz-IdiPAZ, 28046 Madrid, Spain.
Zapater-Moros A; Molecular Oncology Lab, Hospital Universitario La Paz-IdiPAZ, 28046 Madrid, Spain.; Biomedica Molecular Medicine SL, 28049 Madrid, Spain.
López-Camacho E; Biomedica Molecular Medicine SL, 28049 Madrid, Spain.
Lumbreras-Herrera MI; Molecular Oncology Lab, Hospital Universitario La Paz-IdiPAZ, 28046 Madrid, Spain.
Soriano V; Instituto Valenciano de Oncología, 46009 Valencia, Spain.; Spanish Melanoma Group (GEM), 08024 Barcelona, Spain.
Garicano F; Spanish Melanoma Group (GEM), 08024 Barcelona, Spain.; Hospital de Galdakao, 48960 Bizkaia, Spain.
Lecumberri MJ; Spanish Melanoma Group (GEM), 08024 Barcelona, Spain.; Complejo Hospitalario de Navarra, 31008 Pamplona, Spain.
Rodríguez de la Borbolla M; Spanish Melanoma Group (GEM), 08024 Barcelona, Spain.; Hospital de Valme, 41014 Sevilla, Spain.
Majem M; Spanish Melanoma Group (GEM), 08024 Barcelona, Spain.; Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain.
Pérez-Ruiz E; Spanish Melanoma Group (GEM), 08024 Barcelona, Spain.; Hospital Costa del Sol, 29603 Marbella, Spain.
González-Cao M; Spanish Melanoma Group (GEM), 08024 Barcelona, Spain.; Hospital Quirón Dexeus, 08028 Barcelona, Spain.
Oramas J; Spanish Melanoma Group (GEM), 08024 Barcelona, Spain.; Hospital Universitario de Canarias-San Cristóbal de la Laguna, 38320 La Laguna, Spain.
Magdaleno A; Spanish Melanoma Group (GEM), 08024 Barcelona, Spain.; Hospital Universitario de Elche y Vega Baja, 03203 Elche, Spain.
Fra J; Spanish Melanoma Group (GEM), 08024 Barcelona, Spain.; Hospital Universitario Río Hortega, 47012 Valladolid, Spain.
Martín-Carnicero A; Spanish Melanoma Group (GEM), 08024 Barcelona, Spain.; Hospital San Pedro, 26006 Logroño, Spain.
Corral M; Spanish Melanoma Group (GEM), 08024 Barcelona, Spain.; Hospital Clínico Lozano Blesa, 50009 Zaragoza, Spain.
Puértolas T; Spanish Melanoma Group (GEM), 08024 Barcelona, Spain.; Hospital Universitario Miguel Servet, 50009 Zaragoza, Spain.
Ramos R; Genomics Unit, Parque Científico de Madrid, 28049 Madrid, Spain.
Fresno Vara JÁ; Molecular Oncology Lab, Hospital Universitario La Paz-IdiPAZ, 28046 Madrid, Spain.; Biomedica Molecular Medicine SL, 28049 Madrid, Spain.; CIBERONC, ISCIII, 28029 Madrid, Spain.
Espinosa E; Spanish Melanoma Group (GEM), 08024 Barcelona, Spain.; CIBERONC, ISCIII, 28029 Madrid, Spain.; Medical Oncology Service, Hospital Universitario La Paz, 28046 Madrid, Spain.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2023 Jan 02; Vol. 24 (1). Date of Electronic Publication: 2023 Jan 02.
Typ publikacji:: Journal Article
MeSH Terms:: Melanoma*/drug therapy
Melanoma*/genetics
Skin Neoplasms*/drug therapy
Skin Neoplasms*/genetics
Humans ; Transcriptome ; Immune Checkpoint Inhibitors/pharmacology ; Immune Checkpoint Inhibitors/therapeutic use ; Immunotherapy

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Bayesian networks established functional differences between breast cancer subtypes.
Autorzy:: Trilla-Fuertes L; Biomedica Molecular Medicine SL, Madrid, Spain.
Gámez-Pozo A; Biomedica Molecular Medicine SL, Madrid, Spain.; Molecular Oncology & Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM, La Paz University Hospital-IdiPAZ, Madrid, Spain.
Arevalillo JM; Operational Research and Numerical Analysis, National Distance Education University (UNED), Madrid, Spain.
López-Vacas R; Molecular Oncology & Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM, La Paz University Hospital-IdiPAZ, Madrid, Spain.
López-Camacho E; Biomedica Molecular Medicine SL, Madrid, Spain.
Prado-Vázquez G; Biomedica Molecular Medicine SL, Madrid, Spain.; Molecular Oncology & Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM, La Paz University Hospital-IdiPAZ, Madrid, Spain.
Zapater-Moros A; Biomedica Molecular Medicine SL, Madrid, Spain.; Molecular Oncology & Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM, La Paz University Hospital-IdiPAZ, Madrid, Spain.
Díaz-Almirón M; Biostatistics Unit, La Paz University Hospital-IdiPAZ, Madrid, Spain.
Ferrer-Gómez M; Molecular Oncology & Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM, La Paz University Hospital-IdiPAZ, Madrid, Spain.
Navarro H; Operational Research and Numerical Analysis, National Distance Education University (UNED), Madrid, Spain.
Nanni P; Functional Genomics Centre Zurich, University of Zurich/ETH Zurich, Zurich, Switzerland.
Zamora P; Medical Oncology Service, La Paz University Hospital-IdiPAZ, Madrid, Spain.
Espinosa E; Medical Oncology Service, La Paz University Hospital-IdiPAZ, Madrid, Spain.; Biomedical Research Networking Center on Oncology-CIBERONC, ISCIII, Madrid, Spain.
Maín P; Department of Statistics and Operations Research, Faculty of Mathematics, Complutense University of Madrid, Madrid, Spain.
Fresno Vara JÁ; Biomedica Molecular Medicine SL, Madrid, Spain.; Molecular Oncology & Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM, La Paz University Hospital-IdiPAZ, Madrid, Spain.; Biomedical Research Networking Center on Oncology-CIBERONC, ISCIII, Madrid, Spain.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2020 Jun 11; Vol. 15 (6), pp. e0234752. Date of Electronic Publication: 2020 Jun 11 (Print Publication: 2020).
Typ publikacji:: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Proteomics*
Breast Neoplasms/*classification
Breast Neoplasms/*metabolism
Bayes Theorem ; Breast Neoplasms/diagnosis ; Breast Neoplasms/pathology ; Extracellular Matrix/metabolism ; Gene Ontology ; Humans ; Prognosis

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Computational models applied to metabolomics data hints at the relevance of glutamine metabolism in breast cancer.
Autorzy:: Trilla-Fuertes L; Biomedica Molecular Medicine SL, C/ Faraday, 7, 28049, Madrid, Spain.
Gámez-Pozo A; Biomedica Molecular Medicine SL, C/ Faraday, 7, 28049, Madrid, Spain.; Molecular Oncology & Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM, La Paz University Hospital-IdiPAZ, Paseo de la Castellana, 261, 28046, Madrid, Spain.
López-Camacho E; Molecular Oncology & Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM, La Paz University Hospital-IdiPAZ, Paseo de la Castellana, 261, 28046, Madrid, Spain.
Prado-Vázquez G; Biomedica Molecular Medicine SL, C/ Faraday, 7, 28049, Madrid, Spain.
Zapater-Moros A; Biomedica Molecular Medicine SL, C/ Faraday, 7, 28049, Madrid, Spain.; Molecular Oncology & Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM, La Paz University Hospital-IdiPAZ, Paseo de la Castellana, 261, 28046, Madrid, Spain.
López-Vacas R; Molecular Oncology & Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM, La Paz University Hospital-IdiPAZ, Paseo de la Castellana, 261, 28046, Madrid, Spain.
Arevalillo JM; Department of Statistics, Operational Research and Numerical Analysis, National University of Distance Education (UNED), Paseo Senda del Rey, 9, 28040, Madrid, Spain.
Díaz-Almirón M; Biostatistics Unit, La Paz University Hospital-IdiPAZ, Paseo de la Castellana, 261, 28046, Madrid, Spain.
Navarro H; Department of Statistics, Operational Research and Numerical Analysis, National University of Distance Education (UNED), Paseo Senda del Rey, 9, 28040, Madrid, Spain.
Maín P; Department of Statistics and Operations Research, Faculty of Mathematics, Complutense University of Madrid, Plaza de las Ciencias, 3, 28040, Madrid, Spain.
Espinosa E; Medical Oncology Service, La Paz University Hospital-IdiPAZ, Paseo de la Castellana, 261, 28046, Madrid, Spain.; Biomedical Research Networking Center on Oncology-CIBERONC, ISCIII, C/Melchor Fernández Almagro, 3, 28029, Madrid, Spain.
Zamora P; Medical Oncology Service, La Paz University Hospital-IdiPAZ, Paseo de la Castellana, 261, 28046, Madrid, Spain.; Biomedical Research Networking Center on Oncology-CIBERONC, ISCIII, C/Melchor Fernández Almagro, 3, 28029, Madrid, Spain.
Fresno Vara JÁ; Molecular Oncology & Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM, La Paz University Hospital-IdiPAZ, Paseo de la Castellana, 261, 28046, Madrid, Spain. .; Biomedical Research Networking Center on Oncology-CIBERONC, ISCIII, C/Melchor Fernández Almagro, 3, 28029, Madrid, Spain. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2020 Apr 15; Vol. 20 (1), pp. 307. Date of Electronic Publication: 2020 Apr 15.
Typ publikacji:: Journal Article
MeSH Terms:: Metabolic Networks and Pathways*/drug effects
Breast Neoplasms/*metabolism
Gene Expression Profiling/*methods
Glutamine/*metabolism
Metabolomics/*methods
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Breast Neoplasms/drug therapy ; Breast Neoplasms/genetics ; Breast Neoplasms/pathology ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Databases, Genetic ; Female ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; MCF-7 Cells ; Middle Aged ; Models, Theoretical ; Neoplasm Staging

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: Biological molecular layer classification of muscle-invasive bladder cancer opens new treatment opportunities.
Autorzy:: Trilla-Fuertes L; Biomedica Molecular Medicine SL, Madrid, Spain.
Gámez-Pozo A; Biomedica Molecular Medicine SL, Madrid, Spain.; Molecular Oncology & Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain.
Prado-Vázquez G; Biomedica Molecular Medicine SL, Madrid, Spain.
Zapater-Moros A; Biomedica Molecular Medicine SL, Madrid, Spain.; Molecular Oncology & Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain.
Díaz-Almirón M; Biostatistics Unit, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain.
Arevalillo JM; Department of Statistics, Operational Research and Numerical Analysis, Universidad Nacional de Educación a Distancia (UNED), Madrid, Spain.
Ferrer-Gómez M; Molecular Oncology & Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain.
Navarro H; Department of Statistics, Operational Research and Numerical Analysis, Universidad Nacional de Educación a Distancia (UNED), Madrid, Spain.
Maín P; Department of Statistics and Operations Research, Faculty of Mathematics, Complutense University of Madrid, Madrid, Spain.
Espinosa E; Servicio de Oncología Médica, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain.; Biomedical Research Networking Center on Oncology-CIBERONC, ISCIII, Madrid, Spain.
Pinto Á; Servicio de Oncología Médica, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain.; Biomedical Research Networking Center on Oncology-CIBERONC, ISCIII, Madrid, Spain.
Vara JÁF; Molecular Oncology & Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain. .; Biomedical Research Networking Center on Oncology-CIBERONC, ISCIII, Madrid, Spain. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2019 Jun 28; Vol. 19 (1), pp. 636. Date of Electronic Publication: 2019 Jun 28.
Typ publikacji:: Journal Article
MeSH Terms:: Carcinoma, Transitional Cell/*classification
Carcinoma, Transitional Cell/*genetics
Urinary Bladder Neoplasms/*classification
Urinary Bladder Neoplasms/*genetics
Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor/genetics ; Carcinoma, Transitional Cell/metabolism ; Carcinoma, Transitional Cell/therapy ; Extracellular Matrix/metabolism ; Female ; Gene Expression Profiling ; Humans ; Male ; Metabolic Networks and Pathways ; Middle Aged ; Neoplasm Invasiveness ; Receptors, Androgen/genetics ; Urinary Bladder Neoplasms/metabolism ; Urinary Bladder Neoplasms/therapy

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: A novel approach to triple-negative breast cancer molecular classification reveals a luminal immune-positive subgroup with good prognoses.
Autorzy:: Prado-Vázquez G; Molecular Oncology & Pathology Lab, INGEMM, La Paz University Hospital Health Research Institute-IdiPAZ, Madrid, Spain.; R&D department, Biomedica Molecular Medicine SL, Madrid, Spain.
Gámez-Pozo A; Molecular Oncology & Pathology Lab, INGEMM, La Paz University Hospital Health Research Institute-IdiPAZ, Madrid, Spain.; R&D department, Biomedica Molecular Medicine SL, Madrid, Spain.
Trilla-Fuertes L; R&D department, Biomedica Molecular Medicine SL, Madrid, Spain.
Arevalillo JM; Department of Statistics, Operational Research and Numerical Analysis, National University of Distance Education (UNED), Madrid, Spain.
Zapater-Moros A; Molecular Oncology & Pathology Lab, INGEMM, La Paz University Hospital Health Research Institute-IdiPAZ, Madrid, Spain.; R&D department, Biomedica Molecular Medicine SL, Madrid, Spain.
Ferrer-Gómez M; Molecular Oncology & Pathology Lab, INGEMM, La Paz University Hospital Health Research Institute-IdiPAZ, Madrid, Spain.
Díaz-Almirón M; Biostatistics Unit, La Paz University Hospital Health Research Institute-IdiPAZ, Madrid, Spain.
López-Vacas R; Molecular Oncology & Pathology Lab, INGEMM, La Paz University Hospital Health Research Institute-IdiPAZ, Madrid, Spain.
Navarro H; Department of Statistics, Operational Research and Numerical Analysis, National University of Distance Education (UNED), Madrid, Spain.
Maín P; Department of Statistics and Operations Research, Faculty of Mathematics, Complutense University of Madrid, Madrid, Spain.
Feliú J; Medical Oncology Service, La Paz University Hospital Health Research Institute-IdiPAZ, Madrid, Spain.; Biomedical Research Networking Center on Oncology-CIBERONC, ISCIII, Madrid, Spain.
Zamora P; Medical Oncology Service, La Paz University Hospital Health Research Institute-IdiPAZ, Madrid, Spain.
Espinosa E; Medical Oncology Service, La Paz University Hospital Health Research Institute-IdiPAZ, Madrid, Spain.; Biomedical Research Networking Center on Oncology-CIBERONC, ISCIII, Madrid, Spain.
Fresno Vara JÁ; Molecular Oncology & Pathology Lab, INGEMM, La Paz University Hospital Health Research Institute-IdiPAZ, Madrid, Spain. .; Biomedical Research Networking Center on Oncology-CIBERONC, ISCIII, Madrid, Spain. .; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2019 Feb 07; Vol. 9 (1), pp. 1538. Date of Electronic Publication: 2019 Feb 07.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:: Triple Negative Breast Neoplasms/*diagnosis
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cluster Analysis ; Databases, Genetic ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Kaplan-Meier Estimate ; Models, Theoretical ; Neoplasm Grading ; Prognosis ; Triple Negative Breast Neoplasms/drug therapy ; Triple Negative Breast Neoplasms/metabolism

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: Proteomics characterisation of central nervous system metastasis biomarkers in triple negative breast cancer.
Autorzy:: Rojas L K; Department of Medical Oncology, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain.; Katerin L Rojas and Lucía Trilla-Fuertes contributed equally to this work.
Trilla-Fuertes L; Biomedica Molecular Medicine SL, 28049 Madrid, Spain.; Katerin L Rojas and Lucía Trilla-Fuertes contributed equally to this work.
Gámez-Pozo A; Biomedica Molecular Medicine SL, 28049 Madrid, Spain.; Molecular Oncology and Pathology Lab, Instituto de Genética Médica y Molecular-INGEMM, Hospital Universitario La Paz-IdiPAZ, 28029 Madrid, Spain.
Chiva C; Proteomics Unit, Center of Genomics Regulation, Barcelona Institute of Science and Technology, 08036 Barcelona, Spain.; Proteomics Unit, Universitat Pompeu Fabra, 08002 Barcelona, Spain.
Sepúlveda J; Department of Medical Oncology, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain.
Manso L; Department of Medical Oncology, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain.
Prado-Vázquez G; Biomedica Molecular Medicine SL, 28049 Madrid, Spain.; Molecular Oncology and Pathology Lab, Instituto de Genética Médica y Molecular-INGEMM, Hospital Universitario La Paz-IdiPAZ, 28029 Madrid, Spain.
Zapater-Moros A; Biomedica Molecular Medicine SL, 28049 Madrid, Spain.; Molecular Oncology and Pathology Lab, Instituto de Genética Médica y Molecular-INGEMM, Hospital Universitario La Paz-IdiPAZ, 28029 Madrid, Spain.
López-Vacas R; Molecular Oncology and Pathology Lab, Instituto de Genética Médica y Molecular-INGEMM, Hospital Universitario La Paz-IdiPAZ, 28029 Madrid, Spain.
Ferrer-Gómez M; Molecular Oncology and Pathology Lab, Instituto de Genética Médica y Molecular-INGEMM, Hospital Universitario La Paz-IdiPAZ, 28029 Madrid, Spain.
Mendiola C; Department of Medical Oncology, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain.
Espinosa E; Medical Oncology Service, Hospital Universitario La Paz-IdiPAZ, 28029 Madrid, Spain.; CIBERONC, Instituto de Salud Carlos III, 28029 Madrid, Spain.
Sabidó E; Proteomics Unit, Center of Genomics Regulation, Barcelona Institute of Science and Technology, 08036 Barcelona, Spain.; Proteomics Unit, Universitat Pompeu Fabra, 08002 Barcelona, Spain.
Ciruelos E; Department of Medical Oncology, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain.
Vara JÁF; Biomedica Molecular Medicine SL, 28049 Madrid, Spain.; Molecular Oncology and Pathology Lab, Instituto de Genética Médica y Molecular-INGEMM, Hospital Universitario La Paz-IdiPAZ, 28029 Madrid, Spain.; CIBERONC, Instituto de Salud Carlos III, 28029 Madrid, Spain.; Pokaż więcej
Źródło:: Ecancermedicalscience [Ecancermedicalscience] 2019 Jan 15; Vol. 13, pp. 891. Date of Electronic Publication: 2019 Jan 15 (Print Publication: 2019).
Typ publikacji:: Journal Article

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: Prediction of adjuvant chemotherapy response in triple negative breast cancer with discovery and targeted proteomics.
Autorzy:: Gámez-Pozo A; Molecular Oncology & Pathology Lab, Instituto de Genética Médica y Molecular-INGEMM, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain.; Biomedica Molecular Medicine SL, Madrid, Spain.
Trilla-Fuertes L; Biomedica Molecular Medicine SL, Madrid, Spain.
Prado-Vázquez G; Molecular Oncology & Pathology Lab, Instituto de Genética Médica y Molecular-INGEMM, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain.
Chiva C; Proteomics Unit, Center of Genomics Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.; Proteomics Unit, Universitat Pompeu Fabra (UPF), Barcelona, Spain.
López-Vacas R; Molecular Oncology & Pathology Lab, Instituto de Genética Médica y Molecular-INGEMM, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain.
Nanni P; Functional Genomics Centre Zurich, University of Zurich/ETH Zurich, Zurich, Switzerland.
Berges-Soria J; Molecular Oncology & Pathology Lab, Instituto de Genética Médica y Molecular-INGEMM, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain.
Grossmann J; Functional Genomics Centre Zurich, University of Zurich/ETH Zurich, Zurich, Switzerland.
Díaz-Almirón M; Biostatistics Unit, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain.
Ciruelos E; Medical Oncology Service, Instituto de Investigación Hospital Universitario Doce de Octubre-i+12, Madrid, Spain.
Sabidó E; Proteomics Unit, Center of Genomics Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.; Proteomics Unit, Universitat Pompeu Fabra (UPF), Barcelona, Spain.
Espinosa E; Medical Oncology Service, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain.; CIBERONC. Instituto de Salud Carlos III, Madrid, Spain.
Fresno Vara JÁ; Molecular Oncology & Pathology Lab, Instituto de Genética Médica y Molecular-INGEMM, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain.; Biomedica Molecular Medicine SL, Madrid, Spain.; CIBERONC. Instituto de Salud Carlos III, Madrid, Spain.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2017 Jun 08; Vol. 12 (6), pp. e0178296. Date of Electronic Publication: 2017 Jun 08 (Print Publication: 2017).
Typ publikacji:: Journal Article
MeSH Terms:: Chemotherapy, Adjuvant/*methods
Proteomics/*methods
Triple Negative Breast Neoplasms/*drug therapy
Triple Negative Breast Neoplasms/*metabolism
Adult ; Aged ; Aged, 80 and over ; Disease-Free Survival ; Humans ; Middle Aged ; Prognosis ; Software ; Transcriptome/genetics ; Triple Negative Breast Neoplasms/mortality ; Triple Negative Breast Neoplasms/pathology ; rab GTP-Binding Proteins/metabolism ; rac GTP-Binding Proteins/metabolism ; RAC2 GTP-Binding Protein

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Prado-Vázquez, Guillermo"" wg kryterium: Autor

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język